Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVICTUS trial of rivaroxaban versus vitamin K antagonists in rheumatic valvular heart disease with atrial fibrillation or flutter
PACTR202007518001972Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3 trial of rivaroxaban in rheumatic heart disease (RHD), Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Population Health Research Institute. Primary endpoints: Stroke and Systemic embolism. Started Jan 2016; status: completed.
02
Drugs
rivaroxaban
03
Conditions
rheumatic heart disease (RHD)Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on PACTR202007518001972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007518001972.